Literature DB >> 16511408

HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.

Jade Ghosn1, Isabelle Pellegrin, Cécile Goujard, Christiane Deveau, Jean-Paul Viard, Julie Galimand, Martine Harzic, Catherine Tamalet, Laurence Meyer, Christine Rouzioux, Marie-Laure Chaix.   

Abstract

OBJECTIVE: Characterization of the early establishment of the viral reservoir in patients acquiring resistant strains at primary HIV-1 infection (PHI), and longitudinal analysis of resistance mutations in circulating virions and intracellular HIV strains. PATIENTS AND METHODS: Drug-resistance was compared between HIV RNA and peripheral blood mononuclear cell (PBMC)-HIV DNA at the time of PHI in 44 patients enrolled in the Primo Cohort and harbouring plasma HIV-1 resistant to at least one antiretroviral drug. Longitudinal monitoring of viral load and resistance genotype was performed in plasma-HIV RNA and PBMC HIV DNA for at least 24 months in a subset of 10 patients. Phylogenetic analysis of HIV DNA protease gene clones was used to explore the diversity of quasi-species at baseline.
RESULTS: Baseline resistance profile was identical in paired HIV RNA and PBMC HIV DNA for all 44 patients. All resistance-associated mutations persisted in plasma and PBMC over 2 years in the five untreated patients. Of the five patients started on empirical HAART, two achieved undetectable HIV RNA at month 6, with long-term persistence of archived drug-resistance mutations in PBMC HIV DNA. Virological failure was observed in the other three patients, resulting in the accumulation of additional drug-resistance mutations in HIV RNA and HIV DNA for two of them. Phylogenetic analysis of HIV DNA clones showed highly homogenous and exclusively resistant quasi-species in the cellular reservoir at baseline.
CONCLUSION: HIV resistant strains acquired at the time of PHI massively fuel the cellular reservoir, and their prolonged persistence is supported by the early expansion of a dominant homogenous and resistant viral population. Results in treated patients showed that classical empirical triple-combination may be suboptimal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511408     DOI: 10.1097/01.aids.0000199820.47703.a0

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

Review 1.  Primary drug resistance in South Africa: data from 10 years of surveys.

Authors:  Justen Manasa; David Katzenstein; Sharon Cassol; Marie-Louise Newell; Tulio de Oliveira
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-12       Impact factor: 2.205

2.  Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection.

Authors:  Pierre Frange; Marie-Laure Chaix; Stéphanie Raymond; Julie Galimand; Christiane Deveau; Laurence Meyer; Cécile Goujard; Christine Rouzioux; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

Review 3.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

4.  Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.

Authors:  Marie-Laure Chaix; Didier Koumavi Ekouevi; Gilles Peytavin; François Rouet; Besigin Tonwe-Gold; Ida Viho; Laurence Bequet; Clarisse Amani-Bosse; Hervé Menan; Valériane Leroy; Christine Rouzioux; François Dabis
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

5.  Fragment-based screen against HIV protease.

Authors:  Alexander L Perryman; Qing Zhang; Holly H Soutter; Robin Rosenfeld; Duncan E McRee; Arthur J Olson; John E Elder; C David Stout
Journal:  Chem Biol Drug Des       Date:  2010-01-19       Impact factor: 2.817

6.  Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection.

Authors:  J Ghosn; C Deveau; C Goujard; I Garrigue; N Saïchi; J Galimand; Z Nagy; C Rouzioux; L Meyer; M-L Chaix
Journal:  Sex Transm Infect       Date:  2006-08-21       Impact factor: 3.519

7.  Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda.

Authors:  Guinevere Q Lee; David R Bangsberg; Conrad Muzoora; Yap Boum; Jessica H Oyugi; Nneka Emenyonu; John Bennett; Peter W Hunt; David Knapp; Chanson J Brumme; P Richard Harrigan; Jeffrey N Martin
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-29       Impact factor: 2.205

8.  Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome.

Authors:  Constance Delaugerre; Marie-Laure Chaix; Stephane Blanche; Josiane Warszawski; Dorine Cornet; Catherine Dollfus; Veronique Schneider; Marianne Burgard; Albert Faye; Laurent Mandelbrot; Roland Tubiana; Christine Rouzioux
Journal:  Retrovirology       Date:  2009-09-19       Impact factor: 4.602

9.  Transmission cluster of multiclass highly drug-resistant HIV-1 among 9 men who have sex with men in Seattle/King County, WA, 2005-2007.

Authors:  Susan E Buskin; Giovanina M Ellis; Gregory G Pepper; Lisa M Frenkel; Steven A Pergam; Geoffrey S Gottlieb; Carrie Horwitch; Jeffrey F Olliffe; Karen Johnson; Peter Shalit; Corinne Heinen; Margot Schwartz; Robert W Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2008-10-01       Impact factor: 3.731

10.  Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.

Authors:  Zandrea Ambrose; Sarah Palmer; Valerie F Boltz; Mary Kearney; Kay Larsen; Patricia Polacino; Leon Flanary; Kelli Oswald; Michael Piatak; Jeremy Smedley; Wei Shao; Norbert Bischofberger; Frank Maldarelli; Jason T Kimata; John W Mellors; Shiu-Lok Hu; John M Coffin; Jeffrey D Lifson; Vineet N KewalRamani
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.